Methylene blue in human health: from established antidote to therapeutic promise

Approved indication: treatment of methaemoglobinaemia

The condition and its urgency

Methaemoglobinaemia is a rare but potentially fatal condition in which the haemoglobin in the blood loses its capacity to transport oxygen. The ferrous ion (Fe²⁺) of haemoglobin is oxidised to the ferric state (Fe³⁺), forming inert methaemoglobin. The blood becomes unable to oxygenate the tissues, causing cyanosis and cellular hypoxia.

Common causes: accidental poisoning (dietary nitrites, certain medicines), chemical exposure (aniline), rare congenital methaemoglobinaemia.

Symptoms: bluish-grey lips and mucous membranes, headaches, dizziness, confusion, progressive loss of consciousness.

The role of methylene blue

Methylene blue acts as a powerful reducing agent. By accepting two electrons, it reduces ferric iron to the ferrous state, thereby restoring the oxygen-transport function of haemoglobin.

Mechanism:

Methylene blue (oxidised) + Fe³⁺ (methaemoglobin)
→ Reduced blue + Fe²⁺ (functional haemoglobin)

Efficacy: rapid and predictable. The cyanosis usually subsides within five to thirty minutes of intravenous administration. It is the salvage intervention par excellence in this condition.

Established clinical protocol

Standard dosage: 1 to 2 mg/kg of body weight by slow intravenous injection. For a 70 kg adult, this corresponds to roughly 70-140 mg diluted in sterile saline solution.

Administration: intravenous infusion over five to ten minutes. Administration that is too rapid causes pain at the injection site.

Clinical outcome: improvement is quickly observable. Oxygen saturation improves, the cyanosis disappears and the patient regains consciousness.

Safety: the safety profile is excellent as long as the dose remains below 7 mg/kg. Beyond this, there is a risk of haemolysis (destruction of red blood cells) and anaemia.

Regulatory status

Methylene blue is approved in the official pharmacopoeias (USP, Ph.Eur., BP) specifically for this indication. It is one of the few medical applications that are regulatorily established, recognised as the standard treatment in intensive care and emergency medicine.

Applications under investigation: neuroprotection

Theoretical concept

Cognitive degeneration and neurodegenerative diseases such as Alzheimer's and Parkinson's are characterised by mitochondrial dysfunction, accumulation of misfolded proteins and chronic oxidative stress within neurons. Methylene blue, as a mitochondrial electron acceptor and a compound with antioxidant properties, could theoretically curb or slow these degenerative processes.

Preclinical evidence

Laboratory and animal studies show encouraging results. In cultures of neurons exposed to toxic amyloid proteins, the blue reduces cell death. In transgenic mice modelling Alzheimer's disease, chronic administration of the blue slightly improves cognitive performance compared with control animals.

These results suggest genuine potential, but it is worth remembering that rodents are not humans. Promising laboratory results only rarely translate into confirmed clinical benefit.

Clinical trials in progress

A purified derivative of methylene blue called leucomethylthioninium (LMTM) is currently in phase 3 clinical trials for Alzheimer's disease. The partial results reported so far suggest a modest slowing of cognitive decline in certain subgroups of patients, particularly those who had not received other cognitive medicines.

These results nevertheless remain mixed. The observed efficacy is modest, and several earlier trials failed to meet their primary efficacy endpoints. The initial enthusiasm has been tempered as the results have accumulated.

Current state of the evidence

Robust clinical evidence is still lacking. No large-scale trial has demonstrated a definitive benefit in patients suffering from dementia. Before recommending methylene blue for Alzheimer's disease, the medical community is awaiting results from better-designed and larger trials.

Applications under investigation: resistant infections

The context of antimicrobial resistance

Faced with the proliferation of bacteria resistant to conventional antibiotics, the search for new therapeutic strategies has become imperative. Methylene blue possesses antimicrobial properties that operate through mechanisms different from those of classic antibiotics.

Antimicrobial photodynamic therapy

A particularly promising application is antimicrobial photodynamic therapy (aPDT). Methylene blue, when it absorbs specific red light (664 nanometres), generates highly reactive singlet oxygen. This oxygen physically destroys bacterial membranes without the micro-organisms being able to develop genetic resistance.

Clinical applications under exploration: decontamination of chronic infected wounds, endodontic treatment of dental infections, sanitisation of hospital surfaces.

The preliminary results are encouraging, particularly in dentistry, where local access allows precise illumination. These applications nevertheless remain largely experimental in the hospital setting.

Current limitations

Systemic application (treatment of severe generalised infections) runs into difficulties. Light penetrates deep tissues poorly, and the concentration of blue required for systemic efficacy raises toxicological concerns. The approach therefore remains limited to superficial infections or those accessible locally.

Informal and off-label use

Unofficial practices

Some patients explore the use of methylene blue for various conditions without formal clinical validation: chronic fatigue, brain fog, anxiety disorders, sports recovery. These uses generally fall under self-medication based on internet forums or non-medical advice.

Observed dosages

Users generally report moderate doses (0.5 to 2 mg/kg per day) taken orally. These dosages remain theoretically within acceptable safety margins according to the available toxicological data, but no formal study documents their clinical efficacy.

Ethical concerns

The absence of reliable clinical data creates a problematic situation. Patients have no reliable scientific evidence regarding actual efficacy. There is a risk that the use of the blue may delay recourse to treatments whose efficacy is better established.

Drug interactions and contraindications

Notable interactions

Methylene blue interacts with several important classes of medicines. It affects serotonin metabolism, which makes it potentially dangerous when combined with serotonin reuptake inhibitors (SSRIs, tricyclics). This interaction can trigger serotonin syndrome, manifested by agitation, hyperthermia and neuromuscular disturbances.

Combination with metformin (a diabetes treatment) has also been documented as a source of concern. The blue can affect glucose metabolism.

At-risk populations

Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a rare genetic condition affecting cellular antioxidant defence, are at risk of severe haemolysis. Pregnant women should avoid methylene blue as long as formal safety data are lacking.

Current medical recommendations

Established consensus

The majority of medical bodies recognise the efficacy of methylene blue solely for emergency methaemoglobinaemia. It is the only indication for which official recommendations exist.

Stance on exploratory applications

For neuroprotective or antimicrobial applications, the official position remains cautious. Bodies such as the French National Academy of Medicine recommend awaiting more robust clinical trial results before any recommendation for widespread use.

Recommendation for patients

Patients and physicians are advised to explore the unapproved applications of methylene blue within the formal framework of clinical trials where available, rather than through self-medication. This approach protects the patient while contributing to the accumulation of rigorous scientific data.

The status of the blue in therapeutic guidelines

Methylene blue features in emergency and intensive care manuals (the methaemoglobinaemia indication). It does not appear in any official therapeutic guideline for neurology, oncology or infectious diseases.

Certain alternative research bodies recommend it for unvalidated applications, but these recommendations lack the calibre of formal validation that health agencies require.

Conclusion: distinguishing established application from speculation

Methylene blue occupies a unique position in medicine: on one side an indisputable, life-saving application for methaemoglobinaemia; on the other a set of exploratory applications whose efficacy remains uncertain despite seductive theoretical promise.

This distinction deserves to be better understood by the general public, who often receive diluted information in which conjectural applications become blurred with established ones. Scientific rigour demands this distinction, not out of conservatism, but out of respect for the patient, who deserves reliable information on the actual efficacy of the treatments on offer.

Consult the page on the state of scientific research for a detailed overview of the trials in progress.